Special Issue

Bacteriophages: Biology, Therapy and Application

Message from the Guest Editor

Bacteriophages are viruses that can infect and destroy bacteria without any negative effect on human or animal cells. For this reason, it is supposed that they can be used, alone or in combination with other antibacterials, such as antibiotics, antimicrobial peptides or cationic multivalent dendrimers, to treat bacterial infections. Because bacteriophages are often highly selective in targeting bacteria, they are promising alternatives to antibiotics. I invite you to submit manuscripts to this Special Issue concerning bacteriophages, phage-derived proteins and the broadly understood biology of bacteriophages. In addition, manuscripts concerning other phage-related studies are welcome:

- Phage therapy: past, present and future
- Bacterial phage resistance
- Engineered bacteriophage therapeutics
- Genetic analysis of novel bacteriophages
- Characterization of phage–host interactions
- Evolution of bacteriophages
- Bacteriophages in food safety
- Bacteriophage-based techniques for detection of foodborne pathogens

Guest Editor

Dr. Magdalena Plotka
Laboratory of Extremophiles Biology, Department of Microbiology, University of Gdansk, 80-308 Gdansk, Poland

Deadline for manuscript submissions

closed (31 December 2023)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/116261

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI